COCH Stock Forecast & Price Target

Envoy Medical is poised for success in the hearing health market with their innovative product portfolio, including the fully implanted Active Middle Ear Implant (AMEI) and investigational Acclaim CI. The company's financials, such as a projected 12-month price target of $2.50 per share and key metrics like a 55% chance of FDA approval for the Acclaim CI, support a positive outlook. Envoy's recent announcement that the first three patients in the pivotal trial for the Acclaim CI have successfully completed their 12-month endpoint visit further solidifies their position as a potential leader in the market, with the potential to increase market adoption of cochlear implants with their differentiated, fully implanted technology. With Acclaim CI being the first of its kind, granted Breakthrough Device designation by the FDA, and its ability to potentially increase daily usage and drive earlier adoption of CI, Envoy Medical has a promising future ahead.

Envoy Medical is experiencing financial struggles with a net loss of $7.3M, causing the company to lose ($0.07) per share in 2Q26 and fall below estimated losses. While the company is making progress with its modular premarket approval application for its cochlear implant, with one module submitted and the final module projected to be submitted in 2Q27, the lengthy FDA approval process and projected decrease in EPS due to outstanding shares does not bode well for the company's financial future. As a result, Envoy Medical's stock outlook remains negative.